Researchers have discovered a new way in which RAS genes, which are commonly mutated in cancer, may drive tumor growth beyond their well-known role in signaling at the cell surface. Mutant RAS, they ...

Scientists have developed compounds that selectively block a crucial interaction between RAS and the enzyme PI3K, a driver of ...

Data demonstrate BBO-10203 blocks RAS-mediated activation of PI3Kα and strongly inhibits pAKT signaling in tumor cells without affecting glucose ...

We are gratified the FDA has granted Orphan Drug Designation to daraxonrasib for the treatment of pancreatic cancer, a devastating disease with limited therapeutic options and representing a large ...

National Institutes of Health (NIH) scientists and collaborators say they have discovered a new way in which RAS genes, commonly mutated in cancer, may drive tumor growth beyond their well-known role ...

Over 35 years ago, a group led by Dr. Lowy contributed to the early studies that identified RAS as a cancer-causing gene and helped explain how it promotes tumor growth. In this new study, the ...

Researchers at the Francis Crick Institute and Vividion Therapeutics have identified chemical compounds that can precisely block the interaction between the major cancer-driving gene RAS and a key ...

Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients ...

Those are the real heroes of Huntsman Cancer Institute's research endeavor. It's the students and fellows that work in the research labs, albeit overseen by principal investigators like myself.